BRCA1 and ovarian cancer: Veliparib was evaluated in heavily pretreated ovarian cancer patients with BRCA1/2 mutation, and induced tumor responses in 13/50 (26%) women; similarly to experience with olaparib, there was a clear difference in response rates between platinum-resistant and platinum-sensitive disease (20% vs. 35%) [51].